These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 34834551)

  • 21. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
    Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
    J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC.
    Charawi S; Just PA; Savall M; Abitbol S; Traore M; Metzger N; Ravinger R; Cavard C; Terris B; Perret C
    J Pathol; 2019 Apr; 247(4):435-443. PubMed ID: 30566242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
    Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
    J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Bioinformatics Analysis Identifies the Telomerase Inhibitor MST-312 for Treating High-STMN1-Expressing Hepatocellular Carcinoma.
    Wang SJ; Yang PM
    J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33922244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognosis and personalized medicine prediction by integrated whole exome and transcriptome sequencing of hepatocellular carcinoma.
    Li D; Lei L; Wang J; Tang B; Wang J; Dong R; Shi W; Liu G; Zhao T; Wu Y; Zhang Y
    Front Genet; 2023; 14():1075347. PubMed ID: 36816040
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    Torrecilla S; Sia D; Harrington AN; Zhang Z; Cabellos L; Cornella H; Moeini A; Camprecios G; Leow WQ; Fiel MI; Hao K; Bassaganyas L; Mahajan M; Thung SN; Villanueva A; Florman S; Schwartz ME; Llovet JM
    J Hepatol; 2017 Dec; 67(6):1222-1231. PubMed ID: 28843658
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete response of Ctnnb1-mutated tumours to β-catenin suppression by locked nucleic acid antisense in a mouse hepatocarcinogenesis model.
    Delgado E; Okabe H; Preziosi M; Russell JO; Alvarado TF; Oertel M; Nejak-Bowen KN; Zhang Y; Monga SP
    J Hepatol; 2015 Feb; 62(2):380-7. PubMed ID: 25457204
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
    J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma.
    Zhang W; Kong HF; Gao XD; Dong Z; Lu Y; Huang JG; Li H; Yang YP
    World J Gastroenterol; 2020 Sep; 26(35):5287-5301. PubMed ID: 32994688
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Investigation of
    Javanmard D; Najafi M; Babaei MR; Karbalaie Niya MH; Esghaei M; Panahi M; Safarnezhad Tameshkel F; Tavakoli A; Jazayeri SM; Ghaffari H; Ataei-Pirkooh A; Monavari SH; Bokharaei-Salim F
    Infect Agent Cancer; 2020; 15():37. PubMed ID: 32514293
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comprehensive study of epigenetic alterations in hepatocellular carcinoma identifies potential therapeutic targets.
    Bayo J; Fiore EJ; Dominguez LM; Real A; Malvicini M; Rizzo M; Atorrasagasti C; García MG; Argemi J; Martinez ED; Mazzolini GD
    J Hepatol; 2019 Jul; 71(1):78-90. PubMed ID: 30880225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improvement in the Current Therapies for Hepatocellular Carcinoma Using a Systems Medicine Approach.
    Ozcan M; Altay O; Lam S; Turkez H; Aksoy Y; Nielsen J; Uhlen M; Boren J; Mardinoglu A
    Adv Biosyst; 2020 Jun; 4(6):e2000030. PubMed ID: 32529800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting β-catenin in hepatocellular cancers induced by coexpression of mutant β-catenin and K-Ras in mice.
    Tao J; Zhang R; Singh S; Poddar M; Xu E; Oertel M; Chen X; Ganesh S; Abrams M; Monga SP
    Hepatology; 2017 May; 65(5):1581-1599. PubMed ID: 27981621
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Frequency of somatic mutations in
    Lombardo D; Saitta C; Giosa D; Di Tocco FC; Musolino C; Caminiti G; Chines V; Franzè MS; Alibrandi A; Navarra G; Raimondo G; Pollicino T
    Oncol Lett; 2020 Mar; 19(3):2368-2374. PubMed ID: 32194736
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
    Ang C; Miura JT; Gamblin TC; He R; Xiu J; Millis SZ; Gatalica Z; Reddy SK; Yee NS; Abou-Alfa GK
    J Surg Oncol; 2016 Jan; 113(1):55-61. PubMed ID: 26661118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted sequencing of cancer-associated genes in hepatocellular carcinoma using next-generation sequencing.
    Morishita A; Iwama H; Fujihara S; Watanabe M; Fujita K; Tadokoro T; Ohura K; Chiyo T; Sakamoto T; Mimura S; Nomura T; Tani J; Yoneyama H; Okano K; Suzuki Y; Himoto T; Masaki T
    Oncol Lett; 2018 Jan; 15(1):528-532. PubMed ID: 29391887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
    Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
    J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CircZFR promotes hepatocellular carcinoma progression through regulating miR-3619-5p/CTNNB1 axis and activating Wnt/β-catenin pathway.
    Tan A; Li Q; Chen L
    Arch Biochem Biophys; 2019 Jan; 661():196-202. PubMed ID: 30468709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of differential gene expression in adrenocortical tumors harboring beta-catenin (CTNNB1) mutations.
    Durand J; Lampron A; Mazzuco TL; Chapman A; Bourdeau I
    J Clin Endocrinol Metab; 2011 Jul; 96(7):E1206-11. PubMed ID: 21565795
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic polymorphisms in the Wnt/β-catenin pathway genes as predictors of tumor development and survival in patients with hepatitis B virus-associated hepatocellular carcinoma.
    Kim SS; Cho HJ; Lee HY; Park JH; Noh CK; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
    Clin Biochem; 2016 Jul; 49(10-11):792-801. PubMed ID: 26968103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.